We, therefore, conducted the present study to compare the utility of serum levels of FGF23 (iFGF23 or cFGF23) as predictors of BMD loss in patients receiving CHD with adjustment for known bone-related factors. The gene discussed is FGF23; the disease is coronary artery disorder.